The first generation of the technology was developed by Wyss Core Faculty member David Mooney and his team as a cancer vaccine, substantially derisked though a number of studies, and successfully tested in a human Phase I trial in patients with melanoma (for more details see Press and Publications below). Wyss Institute researchers have combined their multidisciplinary expertise from infectious diseases, immunology, drug delivery, materials science, and protein engineering to develop OMNIVAX, a broadly applicable infection vaccine platform with unique capabilities to help overcome these threats. Credit: Wyss Institute at Harvard University ![]() ![]() OMNIVAX vaccine design OMNIVAX vaccines can be easily injected, and generate robust and durable immune responses against pathogens without the need for frequent booster shots. However, there is a constant need for new vaccines due to factors like rapid genetic change in bacterial and viral pathogens, the emergence of antibiotic-resistant bacterial strains, and zoonotic viruses that spontaneously jump from wildlife reservoirs to humans. The current vaccine development and manufacturing process is inadequate at addressing these significant threats to global health, the economy, and biosecurity. ![]() Infectious diseases pose one of the greatest threats to public health, and vaccination campaigns with broad population coverage – arguably the most powerful strategy for preventing, controlling, and treating infectious diseases – have eradicated or significantly reduced the risk of contracting diseases such as smallpox, measles, polio, and tetanus.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |